Flex Pharma Inc News Releases http://ir.flex-pharma.com/ Flex Pharma Inc News Releases en Flex Pharma Reports Second Quarter 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-second-quarter-2018-financial-results BOSTON --(BUSINESS WIRE)--Aug. 1, 2018-- Flex Pharma, Inc . (NASDAQ: FLKS), today announced its financial results for the three months ended June 30, 2018 . On June 13, 2018 , the Company announced that it was ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Motor Neuron Wed, 01 Aug 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8666 Flex Pharma Announces Corporate Update http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-announces-corporate-update -- FLX-787 Phase 2 Clinical Programs in ALS & CMT to Close -- -- FLX-787 Clinical Evaluation of Dysphagia to Continue -- -- Wedbush PacGrow Retained to Guide Assessment of Strategic Alternatives -- -- Restructuring with Workforce Reduction -- BOSTON --(BUSINESS WIRE)--Jun. Wed, 13 Jun 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8601 Flex Pharma Reports First Quarter 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-first-quarter-2018-financial-results -- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS study -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- Conference Call Scheduled Today at 9:00 a.m. ET BOSTON --(BUSINESS WIRE)--May 2, 2018-- Flex Pharma, Inc . (NASDAQ: FLKS), a clinical-stage biotechnology company that Wed, 02 May 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8581 Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018 http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-report-first-quarter-2018-financial-results-may-2 BOSTON --(BUSINESS WIRE)--Apr. 25, 2018-- Flex Pharma, Inc . (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth Wed, 25 Apr 2018 15:19:00 -0400 Flex Pharma Inc News Releases 8571 Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-positive-topline-data-exploratory-phase-2-0 FLX-787 reduced cramp/spasm frequency (p=0.0017) and increased cramp-free days (p=0.0457) in MS patients in a pre-specified analysis of the parallel treatment phase Treating physicians reported improvement in spasticity in patients receiving FLX-787 as measured by the Clinical Global Impression of Mon, 26 Mar 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8551 Flex Pharma Reports Year End 2017 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-year-end-2017-financial-results -- FLX-787 Exploratory MS Spasticity Results at the end of March -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- -- Cash to Mid 2019 -- Conference Call Scheduled Today at 9:00 a.m. ET BOSTON --(BUSINESS WIRE)--Mar. 7, 2018-- Flex Pharma, Inc. Wed, 07 Mar 2018 07:00:00 -0500 Flex Pharma Inc News Releases 8511 Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018 http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-report-fourth-quarter-and-full-year-2017-results BOSTON --(BUSINESS WIRE)--Feb. 28, 2018-- Click to Tweet Flex Pharma, Inc . (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Wed, 28 Feb 2018 16:00:00 -0500 Flex Pharma Inc News Releases 8496 Flex Pharma Presenting at BIO CEO on February 13, 2018 http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-presenting-bio-ceo-february-13-2018 BOSTON --(BUSINESS WIRE)--Feb. 6, 2018-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis Tue, 06 Feb 2018 12:00:00 -0500 Flex Pharma Inc News Releases 8481 Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MS http://ir.flex-pharma.com/news-releases/news-release-details/enrollment-completed-flex-pharmas-phase-2-exploratory-spasticity -- Company to Report Results Late Q1 2018 -- BOSTON --(BUSINESS WIRE)--Nov. 28, 2017-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and Tue, 28 Nov 2017 08:00:00 -0500 Flex Pharma Inc News Releases 8421 Flex Pharma Reports Third Quarter 2017 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-third-quarter-2017-financial-results -- Recent Positive Topline Data Reported from Exploratory Phase 2 Trial of FLX-787 in ALS -- -- Two US Phase 2b Trials in ALS and CMT Initiated under IND; Data Readouts in 2018 -- -- Development Efforts Expanding into Dysphasia -- Conference Call Scheduled Today at 8:45 a.m. Mon, 06 Nov 2017 08:00:00 -0500 Flex Pharma Inc News Releases 8366